Hypoactive sexual desire and erectile dysfunction — evidence across compounds
Every compound the Institute assesses in hypoactive sexual desire and erectile dysfunction, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in hypoactive sexual desire and erectile dysfunction, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| PT-141 (bremelanotide)Melanocortin receptor agonist (cyclic heptapeptide) | Change in Female Sexual Function Index desire domain of +0.30 versus +0.06 with placebo, and improvement in the Female Sexual Distress Scale item 13 of −0.73 versus −0.41 | FSFI-D difference 0.24 (95 % CI 0.14 to 0.34); FSDS-DAO 13 difference −0.32 (95 % CI −0.44 to −0.20) | Moderate | 2 |
| Kisspeptin-10Endogenous decapeptide, KISS1 receptor agonist | Small randomised crossover studies in men with hypoactive sexual desire reported changes in limbic activation on functional imaging and in behavioural measures | very small samples; imaging surrogate endpoints | Low | 1 |
| Melanotan-IINon-selective melanocortin receptor agonist (cyclic… | No adequately powered randomised trial identified for this compound | — | Very low | 0 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
- Melanocortin receptor agonists: approved indications and supplied uses — Low
- PT-141 (bremelanotide) in hypoactive sexual desire and erectile dysfunction: effect on the anchor outcome — Moderate
- PT-141 (bremelanotide) in hypoactive sexual desire and erectile dysfunction: tolerability and discontinuation — Moderate
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.